Implementation of quality by design in vaccine development

BioProcess International

Volumn 11, Issue 2, 2013, Pages 12-17

  Calcott, Peter ^a  

^a Aviation System Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIGENICITY; ARTICLE; BIOPROCESS; QUALITY CONTROL; REPRODUCIBILITY; RISK MANAGEMENT; VACCINATION; VALIDATION PROCESS;

EID: 84874706500     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (20)

1. ICH. Q8 Pharmaceutical Development Q8 (R2), August 2009.
2. ICH. Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), May 2012.
3. Calcott P. How QbD and the FDA Process Validation Guidance Affect Product Development and Operations. BioProcess Int. 9(10) 2011: 14-19.
4. Calcott P. Is QbD Just for Big Pharma? GXP Lifeline June 2012; www.mastercontrol.com/newsletter/pharmaceutical/june-2012.html.
5. Simmerman H, Donnelly RP. Defining Your Product Profile and Maintaining Control Over It, Part 1. BioProcess Intl. 3(6) 2005: 32-40.
6. Champion K, et al. Defining Your Product Profile and Maintaining Control Over It, Part 2. BioProcess Intl. 3(8) 2005: 52-57.
7. Boerner R, Clouse K. Defining Your Product Profile and Maintaining Control Over It, Part 3. BioProcess Intl. 3(9) 2005: 50-56.
8. Brorson K, Phillips J. Defining Your Product Profile and Maintaining Control Over It, Part 4. BioProcess Intl. 3(10) 2005: 50-54.
9. ICH. Q9 Quality Risk Management, November 2005.
10. ICH. Q10 Pharmaceutical Quality Systems, June 2008.
11. Calcott P. FDA Process Validation Guidance Has Celebrated Its First Birthday! How Is the One Year Old Doing? Pharm.Process. January 2012.
12. Calcott P. The EMA 2012 Guidance for Process Validation. GXP Lifeline (publication pending) 2013.
13. Chi-Wan C. Implementation of QbD Principles. CMC Review, 2005; slideshare: www.slideshare.net/bergerb2/quality-by-design.
14. Generic Pharmaceutical Association. Quality by Design for ANDAs: An Example for Modified Release Dosage Forms, 2011.
15. Ho K, Hampson J. Utilisation of QbD Principles for the Management of Postapproval Changes for a Novel Recombinant Monoclonal Antibody: Feedback from Case Study, 2009 EMEA/Efpia QbD Application Workshop, London, UK; www.ema.europa.eu/docs/en-GB/document-library/Presentation/2009/11/WC500008746. pdf.
16. Juran JM. Juran on Quality by Design. Free Press: New York, NY, 1992.
17. Kenett RS, Kenett DA. Quality by Design Applications in Biosimilar Technological Products. Accreditation and Quality Assurance 13(12) 2008: 681-690.
18. Kozlowski S, et al. QbD for Biologics. BioProcess Int. 10(8) 2012: 18-29; www.bioprocessintl.com/journal/2012/September/QbD-for-Biologics-334629.
19. Winkle H. Implementing Quality by Design, PDA/FDA Conference 2007; www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm103453.pdf.
20. Yu L. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharm. Res. 25(4) 2008: 781-791.